Patient Journey, Disease Burden, Treatment Patterns, and the Impact of Delayed Diagnosis Among Patients With Sjögren's Disease: A Real‐World US Survey
ACR Open Rheumatology · 2026-10 · 8 (10)
DOI: 10.1002/acr2.90143 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACR Open Rheumatology, online erschienen am 24.09.2026. Verfasst von Anjana Lalla und 4 weiteren Autor:innen. Beteiligte Einrichtung: Novartis Pharmaceuticals Corporation, East Hanover, New Jersey. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novartis Pharmaceuticals Corporation.
Abstract (Originalsprache)
Objective
The aim of this study was to investigate disease burden, treatment patterns, and impact of delayed diagnosis on patient outcomes in Sjögren's disease (SjD) in a real‐world setting in the United States.
Methods
Data were drawn from the Adelphi Primary Sjögren's Syndrome Disease Specific Programme, a US‐based cross‐sectional collaborative survey between rheumatologists and their next six consecutive consulting patients with SjD. Rheumatologists provided patients’ demographic and clinical information using medical records and a patient‐completed questionnaire.
Results
Rheumatologists (N = 84) provided data on 511 patients with SjD. Calculated Clinical EULAR Sjögren's Syndrome Disease Activity Index (ClinESSDAI)–proxy scores (ps) indicated that patients had mild (44.2%), moderate (30.9%), or severe (24.9%) disease. Among 297 patients, 33.7% had a EULAR Sjögren's Syndrome Patient‐Reported Index (ESSPRI)‐ps of ≥5. Descriptive trends in patient‐reported EuroQoL 5‐Dimension 3‐Level (EQ‐5D‐3L) utility, EuroQoL Visual Analog Scale (EQ‐VAS), Functional Assessment of Chronic Illness Therapy–Fatigue (FACIT‐F), and Work Productivity and Activity Impairment questionnaire scores suggested worsening impairment with increasing SjD severity. Mean (±SD) time to diagnosis was 2.3 (±5.6) years. EQ‐5D‐3L utility ( P = 0.042), EQ‐VAS ( P = 0.026), FACIT‐F ( P = 0.007) scores, and ESSPRI‐ps ( P = 0.001) differed significantly by duration of diagnostic delay. The odds of ClinESSDAI‐ps and ESSPRI‐ps ≥5 at data collection were 2.3 and 2.1 times greater, respectively, in patients diagnosed >12 versus
Autor:innen und Institutionen
- Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.
- Adelphi Real World, Bollington, United Kingdom.
Förderung
- Novartis Pharmaceuticals Corporation
Zitieren
APA
Lalla, A., Egana, A., Milligan, J., Massey, N., & Haughton, J. (2026). Patient Journey, Disease Burden, Treatment Patterns, and the Impact of Delayed Diagnosis Among Patients With Sjögren's Disease: A Real‐World US Survey. ACR Open Rheumatology, 8(10). https://doi.org/10.1002/acr2.90143
Vancouver
Lalla A, Egana A, Milligan J, Massey N, Haughton J. Patient Journey, Disease Burden, Treatment Patterns, and the Impact of Delayed Diagnosis Among Patients With Sjögren's Disease: A Real‐World US Survey. ACR Open Rheumatology. 2026;8(10). doi:10.1002/acr2.90143
BibTeX
@article{Lalla2026,
author = {Lalla, Anjana and Egana, Antton and Milligan, Jack and Massey, Nicola and Haughton, James},
title = {Patient Journey, Disease Burden, Treatment Patterns, and the Impact of Delayed Diagnosis Among Patients With Sjögren's Disease: A Real‐World US Survey},
journal = {ACR Open Rheumatology},
year = {2026},
volume = {8},
number = {10},
doi = {10.1002/acr2.90143}
}
EUVIMED